B-cell maturation antigen (BCMA) was identified as a prognostic marker in multiple myeloma more than two decades ago. Starting in 2014, the first use of BCMA as a treatment target was evaluated in patients with multiple myeloma who received chimeric antigen receptor (CAR) T cells.1,2 Today, a range of myeloma treatments target BCMA, including CAR T cells, along with antibody drug conjugates and bispecific antibodies; some agents are in development, and some have been approved by the Food and Drug Administration (FDA).3 The rapid translation from preclinical studies to several FDA-approved treatments is a new chapter in the remarkable success . . .
Funding and Disclosures
Print Subscriber? Activate your online access.